We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes: relationship with Th17 cytokine profile.
- Authors
Avalos-Navarro, Guadalupe; Muñoz-Valle, José Francisco; Daneri-Navarro, Adrian; Quintero-Ramos, Antonio; Franco-Topete, Ramon Antonio; Morán-Mendoza, Andres de Jesus; Oceguera-Villanueva, Antonio; Bautista-Herrera, Luis Alberto; Topete-Camacho, Antonio; Del Toro-Arreola, Alicia
- Abstract
Breast cancer (BC) is a health problem worldwide; there is evidence that inflammatory cytokines are increased in BC. Macrophage migration inhibitory factor (MIF) has multiple effects on immune cells, inflammation and cancer. Besides, in previous studies, contradictory and uncertain results have been presented on the implication of Th17 cytokine profile in BC. The aim of this study was to evaluate the plasma levels of MIF and the Th17 cytokine profile in BC and their association with their molecular subtypes and clinical stage. A total of 150 women with BC of Ella Binational Breast Cancer Study and 60 healthy women (HW) were evaluated in cross-sectional study. The molecular subtypes were identified by immunohistochemistry. The plasma levels of MIF were quantified by ELISA and Th17 cytokine profile by multiplex system. MIF and IL-17 were significantly increased in BC versus HW (11.1 vs. 5.2 ng/mL and 14.8 pg/mL vs. 2.5 pg/mL p < 0.001, respectively). Our analysis showed that both MIF and IL-17A were associated with increased risk of breast cancer (OR 3.85 CI 95% 1.98–7.50 and OR 4.51 95% 1.83–11.15, respectively), higher in aggressive subtypes Luminal B, HER2 and TN. Likewise, we observed positive correlation between MIF and IL-17A (p < 0.001). In addition, IL-17E was lower in BC versus HW (p <0.001). Likewise, we observed a positive correlation between MIF and IL-17A (p < 0.001). In conclusion, both MIF and IL-17A were associated with high risk for breast cancer and aggressive molecular subtypes.
- Subjects
MACROPHAGE migration inhibitory factor; BREAST cancer; MOLECULAR association
- Publication
Clinical & Experimental Medicine, 2019, Vol 19, Issue 3, p385
- ISSN
1591-8890
- Publication type
Article
- DOI
10.1007/s10238-019-00559-6